Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease.

A patient with obstruction of the terminal ileum from Crohn's disease developed complete paralysis in week 1 of hospitalization. Features initially suggested Guillain-Barre syndrome, but botulinum toxin was identified in serum and stool specimens from week 1 and type A toxin-producing Clostridium botulinum in stool specimens from weeks 3 to 19, confirming botulism due to intestinal colonization. In week 19, the inflamed small bowel was resected, and C. botulinum disappeared from the stool. In week 31, the patient was able to breath without assistance. Testing for an active immune response with neutralizing antibodies to C. botulinum at week 19 was positive; these antibodies remained at a protective level for >1 year. Intestinal colonization botulism, rare in adults, should be considered for patients with descending paralysis, especially those with a preceding alteration in small bowel function. An active immune response to botulinum toxin with production of protective antibodies has not been demonstrated previously in a patient with botulism and may have contributed to this patient's recovery.

Cryptosporidium infection in Oregon public health clinic patients 1985-88: the value of statewide laboratory surveillance.

To evaluate the utility of statewide laboratory Cryptosporidium surveillance, we screened stools from all 5,256 patients evaluated at local health departments for parasitic disease from January 1985 through June 1988. Fifty-seven patients (1.1 percent) were found to have Cryptosporidium. Seasonal peaks in positivity were observed in the spring, summer, and early autumn months. In children, younger age was associated with higher positivity rate of cryptosporidiosis. As a result of these surveillance efforts, Oregon's first known outbreak of cryptosporidiosis was detected and investigated during 1988. Twenty-five persons were infected, including children, parents, and staff associated with two day care centers. The cost of routine screening for Cryptosporidium was $1.13 per specimen in our laboratory, and we consider it useful.

Screening for coinfection with Cryptosporidium and Giardia in Oregon public health clinic patients.

During 1984, we screened 1,710 local public health clinic patients for Giardia and Cryptosporidium. Six patients (0.35 per cent) were positive for Cryptosporidium, and 214 (12.5 per cent) were positive for Giardia. One patient was positive for both parasites. In contrast to other reported studies, no evidence was found for an association between the two parasites (odds ratio = 1.39, 95 per cent CI 0.16, 11.8). The apparent prevalence of Cryptosporidium in our study population was lower than has been reported previously. More laboratory screening could contribute to a better understanding of the distribution of Cryptosporidium and its role in human diarrheal disease, especially in immunocompetent patients.